Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of bifidobacterium longum BL21 and microbial inoculum containing bifidobacterium longum BL21 in preparation of products for preventing, relieving or treating colorectal cancer

A technology of Bifidobacterium longum and colorectal cancer, which is applied in the field of microbiology to achieve the effect of improving the micro-ecological environment, good acid and bile salt resistance, and ensuring balance

Pending Publication Date: 2022-08-05
JIANGSU WECARE BIOTECHNOLOGY CO LTD
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, the strategies for preventing, alleviating or treating colorectal cancer using probiotic preparations in the prior art are still very limited, and the prevention, alleviating or treating effects of these preparations also need to be improved. New strategy for rectal cancer has important implications

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of bifidobacterium longum BL21 and microbial inoculum containing bifidobacterium longum BL21 in preparation of products for preventing, relieving or treating colorectal cancer
  • Application of bifidobacterium longum BL21 and microbial inoculum containing bifidobacterium longum BL21 in preparation of products for preventing, relieving or treating colorectal cancer
  • Application of bifidobacterium longum BL21 and microbial inoculum containing bifidobacterium longum BL21 in preparation of products for preventing, relieving or treating colorectal cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0081] Tolerance analysis of Bifidobacterium longum BL21 to simulated gastrointestinal fluid

[0082] (1) Tolerance of Bifidobacterium longum BL21 to simulated gastric juice

[0083] Bifidobacterium longum BL21 was inoculated into MRS medium at 1%, cultured at 37°C for 16 hours, and centrifuged at 8000 rpm for 5 minutes to collect the bacteria. The bacteria were resuspended in 9 mL of artificial simulated gastric juice with pH 2.0, 2.5 and 3.0 (MRS medium containing 1% pepsin, pH 2.0, 2.5 and 3.0) and left anaerobically at 37°C. Culture for 3h, take samples after 0h and 3h of treatment respectively, measure the number of viable bacteria by pouring culture method and calculate the survival rate, the formula is as follows:

[0084] Survival rate (%)=number of viable bacteria after treatment for 3h / initial number of viable bacteria×100%.

[0085] The test results are shown in Table 1.

[0086] Table 1 Tolerance of Bifidobacterium longum BL21 to simulated gastric juice

[0087...

Embodiment 2

[0097] Adhesion of Bifidobacterium longum BL21 to HT-29 cells in vitro

[0098] 1. HT-29 cell culture passage

[0099] Take out the cryovial containing HT-29 cells from the ultra-low temperature freezer, immediately put it into a constant temperature water bath at 37°C, shake it slightly to make it thaw quickly within 1-1.5min, take out the cryovial, and rinse it with 75% alcohol. After disinfection, put it in the ultra-clean bench. Aspirate the cell suspension into a centrifuge tube with a pipette, add 2mL RPMI 1640 medium (containing 10% double antibody, 1% fetal bovine serum), gently pipette and mix, centrifuge at 1080r / min for 5min, carefully aspirate and discard the cell suspension. Then add 3mL RPMI 1640 medium (containing 10% double antibody, 1% fetal bovine serum), resuspend the cells by gently pipetting, suck the cell suspension into a 25mL culture flask with a pipette, and then add RPMI1640 Culture medium to a total volume of 5 mL, then place at 37 °C, 5% CO 2 Aft...

Embodiment 3

[0108] Inhibitory ability of Bifidobacterium longum BL21 on HT-29 cells

[0109] After the HT-29 cells were cultured and passaged according to the method of Example 2, the cells in log phase were collected, and after digestion with trypsin-EDTA, 4 mL of culture medium was added to terminate the digestion, the cells were resuspended by pipetting, and the cells were counted to estimate the number of cells. , and then adjust the cell concentration to 1 × 10 with the medium 5 / mL, take 100 μL of cell suspension and inoculate it in the middle well of a 96-well plate, and place it at 37°C, 5% CO. 2 The cells were cultured in a cell incubator. After the cells had completely adhered to the wall, the old culture medium was discarded, and 100 μL of RPMI 1640 medium (antibody-free) was added for grouping experiments. A total of 6 groups were set up in the experiment, including Bifidobacterium longum BL21 group, Lactobacillus rhamnosus LRa05 group, BL21+LRa05 combined group, Bifidobacter...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of bifidobacterium longum BL21 and a microbial inoculum containing the bifidobacterium longum BL21 in preparation of products for preventing, relieving or treating colorectal cancer. The bifidobacterium longum BL21 has excellent acid-resistant and cholate-resistant capabilities and good cell adhesion capability, can improve the gene expression level of pro-apoptosis factors CASP3 and Bax and reduce the gene expression level of anti-apoptosis factors Bcl-xl and Bcl-2 by regulating the expression of genes related to apoptosis of the colorectal tumor cells of mice, induces apoptosis of the colorectal tumor cells of the mice, and can be used for preparing the bifidobacterium longum BL21. In addition, the bifidobacterium longum BL21 can be used for remarkably relieving the inflammatory response of the colon part of a colorectal cancer model mouse, relieving the oxidative stress injury of the colorectal cancer model mouse, improving the micro-ecological environment of intestinal flora and maintaining the intestinal health, so that the bifidobacterium longum BL21 can be used for remarkably relieving the inflammatory response of the colon part of the colorectal cancer model mouse. The method has a wide prospect in preparation of products for preventing or treating colorectal cancer.

Description

technical field [0001] The invention belongs to the technical field of microorganisms, and relates to the application of Bifidobacterium longum BL21 and a bacterial agent containing the same in the preparation of products for preventing, relieving or treating colorectal cancer. Background technique [0002] Colorectal cancer (CRC) is a general term for colon cancer and rectal cancer, which is a malignant tumor that occurs in the colon or rectum of the lower digestive tract of the human body. It is a common gastrointestinal malignancy caused by a variety of factors, such as lifestyles such as improper diets due to genetic factors. In addition, a large number of studies have also shown that CRC is closely related to intestinal flora, becoming the most common disease in the world. One of the three major cancers, its mortality rate is second only to lung cancer in men and second only to breast cancer in women, and the incidence and mortality of colorectal cancer have been increa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A23L33/135A61K35/745A61K35/747A61P35/00
CPCA23L33/135A61K35/745A61K35/747A61P35/00A23V2002/00A23V2400/533A23V2200/30A23V2200/308A23V2200/3204A61K2300/00Y02A50/30
Inventor 方曙光郭晓娟汪欣朱建国
Owner JIANGSU WECARE BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com